Form D · Pharmaceuticals

NeurogesX Inc

San Mateo, CA · CIK 0001385830

Offering snapshot reported Nov 27, 2012 · SEC filing

Reported sold
$684K
Offering amount: $684K
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 12, 2012
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 27, 2012Initial$684,300No comparison1SEC filing
Mar 29, 2012Initial$975,000No comparison1SEC filing
Feb 8, 2012Initial$2,999,382No comparison6SEC filing
Aug 17, 2011Initial$1,425,000No comparison1SEC filing
Aug 3, 2011Initial$20,209,229No comparison29SEC filing
Jan 16, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Option to acquire, Security to be acquired
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-187469

Source: Form D, filed Nov 27, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jean Jacques Bienaime Director
Anthony Di Tonno Director
Stephen F. Ghiglieri Executive
Bradford Goodwin Director
Neil Kurtz Director
Gary Lyons Director
Michael Markels Executive
Ronald A. Martell Director, Executive
Robert Nelsen Director
Steven Nelson Director
John Orwin Director
Stephen Peroutka Executive
Jeffrey K. Tobias Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
999 Baker Way Suite 200
San Mateo, CA, 94404